Skip to content
Stack & save: 10% off 3+ vials, 15% off 5+ · Free shipping over $250
Cart 0
Compound Files

CJC-1295 No DAC Research Guide: Names, Structure, and Evidence

Understand Hero CJC-1295 No DAC, why the DAC distinction matters, which published studies used a different structure, and what to document for laboratory work.

Hero Peptides Research TeamUpdated Nov 20265 min read

Quick facts

Catalog name CJC-1295 No DAC
Research context Modified GHRH/GRF analog terminology
Hero vial sizes 5 mg and 10 mg
DAC distinction Albumin-binding modification is absent from the stated catalog version
Documentation priority Verify precise sequence, termini, and chemical form
Hero product CJC-1295 No DAC

CJC-1295 No DAC is a catalog name that requires attention to the final two words. Hero’s material is identified as the No DAC version. The long-acting CJC-1295 compound in several frequently cited studies used an albumin-binding design, so those results cannot simply be assigned to a different structure.

Hero Peptides lists CJC-1295 No DAC research material in 5 mg and 10 mg vials. This guide explains the naming issue, places the GHRH-related research in context, and identifies which product details need verification before comparing an experiment with the published literature.

CJC-1295 No DAC. View catalog product

Origin story: why the modification belongs in the name

A 2005 study investigated modified growth hormone-releasing factor and albumin bioconjugates in rat pituitary systems and rats. It identified CJC-1295 as a long-lasting analog. The albumin-binding design was a central part of that research, not a minor packaging detail (Jetté et al., 2005).

The later clinical paper likewise described a long-acting CJC-1295 preparation. It examined pharmacokinetic and hormone-response measurements in healthy adults. Its findings belong to the tested compound and study conditions (Teichman et al., 2006).

Commercial terminology can blur the boundary between that compound and materials called modified GRF or CJC-1295 No DAC. Use Hero’s stated No DAC identity as the starting point, then verify the precise structure against the lot specification. Do not use a naming convention as a substitute for chemical identification.

How the GHRH research question is framed

GHRH-related analog research asks how a modified peptide interacts with the GHRH receptor and affects downstream measurements in a suitable model. This differs from the ghrelin-receptor pathway associated with secretagogues such as ipamorelin.

A useful experiment separates target activity from duration of exposure. Removing or adding an albumin-binding modification changes the structure being studied. A shared peptide core does not independently establish identical exposure or pharmacodynamic behavior.

The DAC vs No DAC comparison develops that distinction. For a materials section, retain the complete identity rather than shortening both names to CJC-1295 after the first mention.

Also identify the actual endpoint. Receptor signaling, hormone release, and circulating hormone measurements represent different layers. Evidence at one layer can motivate a hypothesis at another, but it does not replace a direct measurement.

Key studies: what the famous papers actually tested

Source Test material or setting Useful contribution Boundary for Hero No DAC
Jetté et al., 2005 GRF analog and albumin-bioconjugate research in rat systems Structure and albumin-binding context Match the precise structure before applying results
Teichman et al., 2006 Long-acting CJC-1295 in healthy adults Exposure and hormone-response measurements Not a direct trial of Hero’s No DAC material
Lot specification Hero’s supplied research material Stated sequence, modifications, and test results Does not independently establish clinical or functional outcomes

The 2006 paper reported prolonged hormone responses following the long-acting preparation. Quoting those durations as a half-life or response period for a No DAC vial would erase the structural distinction that helped produce the research question (Teichman et al., 2006).

For a literature table, add a dedicated column for DAC status and exact test material. If the paper does not clearly establish a match, keep that uncertainty visible. A precise unanswered question is more useful than an apparently complete but mismatched evidence summary.

The GHRH and ghrelin signaling guide provides the broader pathway context. It can help explain why two compounds discussed together still need separate materials descriptions and controls.

Weak spots: naming ambiguity and borrowed evidence

FDA’s safety-risk information flags characterization and immunogenicity concerns for CJC-1295 preparations and notes limited clinical data. That broad record should not be treated as a precise characterization of Hero’s separately specified No DAC material (FDA, 2026).

As of November 17, 2026, this guide does not establish an approved clinical use for Hero CJC-1295 No DAC. It also does not assign a clinical half-life, a hormone-response duration, or a validated human outcome to the supplied vial.

The absence of DAC does not by itself establish every remaining structural detail. Confirm the sequence, termini, modifications, and stated form required by the method. Where documentation is incomplete, obtain clarification before reporting a precise molecular identity.

Purity and identity measurements cannot repair a mismatch between a paper’s compound and the intended test material. First establish what structure the question concerns. Then assess whether the lot documentation and experimental controls are suitable.

Handling CJC-1295 No DAC in the lab

Hero’s 5 mg and 10 mg formats describe nominal material mass. Use the lot documentation and assay requirements to select preparation conditions. A paper on an albumin-binding preparation is not automatically an appropriate preparation reference for this version.

For arithmetic only, nominal 5 mg at a final volume of 2 mL gives 2.5 mg/mL. At a final volume of 4 mL, it gives 1.25 mg/mL. A nominal 10 mg amount at a final volume of 2 mL gives 5 mg/mL. These examples illustrate division and do not establish solvent compatibility or a suitable biological test concentration.

For molar comparisons, use the molecular-weight basis for the documented No DAC material. Do not substitute a mass value from a DAC-containing structure. Record any uncertainty in chemical form rather than hiding it inside a calculated concentration.

The calculator checks mass-per-volume arithmetic. The COA guide explains how the analytical report fits into a complete materials record.

Hero’s supplied catalog identifies Northfield Analytical for HPLC and mass-spectrometry testing. Match the report to the actual lot, and retain solvent, final-volume, date, and dilution records alongside it. Do not infer unreported tests from the testing partner’s name.

CJC-1295 No DAC FAQ

What does No DAC mean here?

It identifies Hero’s stated version as lacking the DAC albumin-binding modification. Verify the complete material identity in the lot documentation.

Are modified GRF and CJC-1295 No DAC always equivalent labels?

The names are often used together commercially, but a label alone does not establish chemical equivalence. Check sequence, termini, and modifications.

Can the long-acting CJC-1295 study establish this vial’s half-life?

No. Its findings concern the tested long-acting compound. A different structure requires evidence relevant to that structure and setting.

What is Hero CJC-1295 No DAC?

It is Hero Peptides’ No DAC research material in 5 mg and 10 mg vials. Consult the product listing and matching lot documentation for supplied specifications.

CJC-1295 No DAC. View catalog product

References

  1. Jetté L, et al. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-3058. Source.
  2. Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. Source.
  3. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Current page checked November 17, 2026. Source.
For laboratory research use only. Not for human or veterinary use. This article is educational and is not medical advice.

Read next

Add 3 vials for 10% off
Build my stack